Find verified Nirogacestat API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Nirogacestat for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Nirogacestat API.
Alternate Names: Nirogacestatum, AS-56178
CAS No: 1290543-63-3
PubChem CID: 46224413
Mol Formula: C27H41F2N5O
Mol Weight: 489.6 g/mol
IUPAC Name: (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide -Show More
API Description: Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. Desmoid tumors are typically characterized by aberrant activation in Notch signaling. Interaction between the notch receptors and their ligands activates proteolytic cleavage by gamma-secretase; therefore, the inhibition of gamma-secretase can potentially inhibit Notch signaling and thus impede the growth of desmoid tumors. Nirogacestat was approved under the brand name OGSIVEO on November 27, 2023, by the FDA for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase 3 DeFi trial, where a confirmed objective response rate was observed to be 41% compared to 8% with the placebo.
